Respiratory Infections

In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.

Preprint data show a US-based variant has come to represent more than 27% and 11% of all sequenced genomes in Louisiana and New Mexico, respectively, through mid-January.

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

The EUA follows the authorization for lone therapy bamlanivimab for adults and children at risk of severe COVID-19.

Implications for antimicrobial use and antimicrobial resistance.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Avian flu outbreaks have been detected in countries all over the world, but influenza activity in humans remains uncharacteristically low for this point in the season.

An online survey-based assessment showed older adults and minorities have been more likely to wear masks in public.

The agency set a PDUFA date for July 18 for Merck's V114 vaccine.

Ability for rapid diagnosis to treat and prevent communicable diseases is a public health issue that goes beyond the current pandemic.

The discovery of unique virus traits may explain why some patients have more severe responses to the disease.

The ability to monitor, mitigate, and prevent new variant spread could influence the odds of majority immunity.

More transmissible variants are emerging quickly. An expert explains why it's expected, but concerning.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

A new multicenter study confirms earlier findings that the panel performs well against the more time-intensive quantitative bacterial culture.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.